Together with our results showing that angiogenic regulator releases from diabetic and non-diabetic platelets were similar (Fig 2), and that supplementation of platelet releasates from patients and controls had identical effects on ECFC tube formation (Fig 3), these three pieces of evidence indicate that platelet α-granule contents/release of angiogenic regulators and platelet membrane components involved in platelet-enhanced angiogenesis (e.g., CD151) are unaltered in well controlled/mild T2DM patients. Here, CD151 is linked to type 2 diabetes mellitus.